ArticleCancer medicine2026
A Multicenter Retrospective Comparative Analysis of Therapeutic Outcomes in Multiple Myeloma Patients Receiving Varied Ixazomib Dosage Regimens.
Article in Cancer medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
Abstract
backgroundMultiple myeloma (MM) is an incurable hematologic malignancy, requiring sustained therapeutic management to mitigate disease recurrence. Ixazomib, a first-generation oral proteasome inhibitor, has exhibited substantial clinical efficacy and is widely employed in clinical practice. According to prescribing guidelines, ixazomib is typically administered at an initial dose of 4 mg weekly for 3 weeks, with dose reduction to 3 mg weekly in the event of adverse effects. Prior exposure-response analyses have confirmed that both 3 and 4 mg doses reside within the clinically effective range. This study aims to assess the comparative efficacy and toxicity profiles of 3 versus 4 mg ixazomib in MM.
methodsWe performed a retrospective analysis of 207 MM patients undergoing ixazomib-based therapy across six medical centers. Patients were stratified into three subgroups: initial treatment, in-class transition, and maintenance/continuation therapy group. Additionally, patients were categorized into two cohorts according to ixazomib dosage: 3 or 4 mg. Demographic characteristics, baseline clinical features, and therapeutic outcomes were compared between the 3 and 4 mg cohorts.
resultsOur results indicate that 3 and 4 mg ixazomib demonstrate equivalent efficacy in induction, class-switch, and maintenance/continuation therapy across most clinical scenarios in Chinese MM patients. Subgroup analysis within the in-class transition cohort revealed that patients with RISS Stage 3 disease exhibited prolonged progression-free survival in the 4 mg group. Furthermore, patients with an ECOG performance status of one to two achieved enhanced overall survival with the 4 mg dose. The overall adverse event rates were comparable between the two dose groups. Notably, during the induction phase, the 4 mg group exhibited a significantly higher incidence of Grades 1-2 vomiting (p = 0.016).
conclusionsThese findings suggest that initiating therapy with 3 mg ixazomib is both clinically viable and effective, potentially alleviating the economic burden for MM patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.